Simulations Plus has partnered with an unnamed clinical-stage biotech company to develop a new delivery model using its GastroPlus software, the company announced Wednesday.
The Lancaster drug simulation company hopes the funded collaboration will improve drug dosing into joints, Simulations said in a statement.
“We intend to incorporate a mechanistic model for different species and population groups that will allow for efficient evaluation of (intra-articular) injection strategies,” Viera Lukacova, director of Simulation Sciences for Simulations Plus, said in a statement. “This will provide a framework to support similar approaches for other drugs.”
“These agreements help to extend the industry-leading capabilities of our software tools, while at the same time increasing the investment that Simulations Plus contributes toward new research initiatives,” added John DiBella, president of the Lancaster division at Simulations Plus.
Simulations Plus maintains the right to license new functionality to all clients for additional revenue streams, DiBella explained.
Shares of Simulation Plus (SLP) closed Thursday up 45 cents, or 1.3 percent, to $36.22 on the Nasdaq.